Biocure Technology Inc is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It is in the process of preclinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEGFilgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.
Quote | Biocure Technology Inc (OTCMKTS:BICTF)
Last: | $0.07 |
---|---|
Change Percent: | 0.0% |
Open: | $0.07 |
Close: | $0.07 |
High: | $0.07 |
Low: | $0.07 |
Volume: | 1,000 |
Last Trade Date Time: | 08/30/2023 03:00:00 am |
News | Biocure Technology Inc (OTCMKTS:BICTF)
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2023) - Biocure Technology Inc. (CSE: CURE) ("CURE" or the "Company") announces that it has entered into an exclusive letter agreement dated September 8, 2023 with Atriva Therapeutics GmbH. ("Atriva") whereby the Company will acquire al...
Vancouver, British Columbia--(Newsfile Corp. - March 25, 2022) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) ("Biocure" or the "Company") is pleased to provide the following operational and investment update to the market and its stakeholders. BPK is currently under way to develop ROR...
Message Board Posts | Biocure Technology Inc (OTCMKTS:BICTF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Biocure Technology Inc Company Name:
BICTF Stock Symbol:
OTCMKTS Market:
Biocure Technology Inc Website:
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2023) - Biocure Technology Inc. (CSE: CURE) ("CURE" or the "Company") announces that it has entered into an exclusive letter agreement dated September 8, 2023 with Atriva Therapeutics GmbH. ("Atriva") whereby the Company will acquire al...
Vancouver, British Columbia--(Newsfile Corp. - March 25, 2022) - Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) ("Biocure" or the "Company") is pleased to provide the following operational and investment update to the market and its stakeholders. BPK is currently under way to develop ROR...
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2021) - Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("Biocure" or the "Company") is pleased to provide the following operational and investment update to the market and its stakeholders. The Company continues to build financi...